Loading…
← CockpitCompetitor Analysis › 2630.HK Vigonvita Life Sciences Co., Ltd. Class HOpen in the cockpit ↗

Vigonvita Life Sciences Co., Ltd. Class H2630.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Generic

Chinese biopharma discovering small-molecule drugs in neuropsychiatry, reproductive health and viral infection, incl. antiviral VV116.

≈ A small Chinese antiviral/CNS drug developerMomentum strong 64
Mkt cap
$1.59B
US dollars, full cap
Free float
26%
of shares outstanding
$/day
$1.69M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-58.7 pp
WACC 18.1%
Hurdle
n/a
no reverse DCF
Close · HKDHK$76.00
1D+1.1%
1W+1.3%
1M-5.0%
3M-8.3%
6M-4.9%
YTD-7.2%
1Y+43.8%
ATR %7.3%
52w lowhigh43.7% off high

What Vigonvita Life Sciences does

Chinese biopharma discovering small-molecule drugs in neuropsychiatry, reproductive health and viral infection, incl. antiviral VV116.

Partner Junshi sells VV116, its antiviral for COVID, in China under a license, so Vigonvita is paid through milestones and a share of sales rather than selling it itself. Sales of such drugs depend heavily on infection waves, which have eased since the pandemic.

In one line: A small Chinese antiviral/CNS drug developer.

Products and services

  • VV116 antiviral (licensed to partners)
  • Neuropsychiatry drugs
  • Reproductive health drugs
  • Generic drugs (4 approved)

Customers

  • Hospitals
  • Pharmacies
  • Licensing partners (Junshi, Simcere)

Where it sits in the supply chain

  • Pharmaceuticals
  • Small-molecule drug discovery
  • Branded + generic drugs

What could go right

  • New drug approvals and licensing deals

What could go wrong

  • COVID-drug revenue declining as pandemic recedes
  • Clinical/pipeline risk

Moat: narrow (IP / patents, regulatory licence). Owns IP on approved antiviral/CNS molecules and out-licenses commercialization rights.

Headquarters: Suzhou, China · Founded: 2013

Named competitors

Vigonvita Life Sciences at a glance

Size Vigonvita Life Sciences (2630.HK) is a Hong Kong Health Care company (Pharmaceuticals: Generic) with a market value of $1.59B, the 459th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$76.00 on 18 Nov 2026.

Performance Over six months the shares fell 4.9%, against -12.5% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 3rd highest of 6 in its peer set.

Growth Revenue grew 763.1% over the last twelve months (peer median -3.9%); the operating margin is -327.4% (peer median 0.5%).

Valuation It trades at 116.9× enterprise value to sales against a peer median of 19.2× (most expensive of 6).

Capital Return on invested capital runs 58.7 points below its cost of capital (18.1% WACC).

Relative performance

10015021 May 202621 Aug 202618 Nov 20262630.HK 99Peer median 88
Six months, rebased to 100: Vigonvita Life Sciences against the median of its 5 peers (local-currency closes).

Vigonvita Life Sciences financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023
Revenuen/aHK$111MHK$12.8MHK$221M
Revenue growth—+763%-94%—
Gross profitn/aHK$61.9M-HK$26.7MHK$214M
EBITDAn/a-HK$318M-HK$186Mn/a
Net incomen/a-HK$386M-HK$229MHK$13.4M
Free cash flown/a-HK$299M-HK$218Mn/a
Capital expendituren/aHK$178MHK$95.6Mn/a
Total debtn/aHK$720MHK$443MHK$365M

Quarterly statements and history in the cockpit →

Vigonvita Life Sciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%NEU6938002589HIK3010752630.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Vigonvita Life Sciences is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%+600%+800%0×50×100×NEU6938002589HIK3010752630.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Vigonvita Life Sciences is the large dot.

Vigonvita Life Sciences competitors and peer comparison

Head to head with its named competitors (2630.HK vs 1877.HK vs 2096.HK vs 2196.HK)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Vigonvita Life Sciences 2630.HK$1.59B-5%+763%-327%116.9×n/a
Shanghai Junshi Biosciences 1877.HK$3.49B-38%+36%-14%8.4×n/a
Simcere Pharmaceutical 2096.HK$3.42B-5%+27%18%2.6×-3.4%
Shanghai Fosun Pharmaceutical (Group) 2196.HK$7.74B-15%+10%6%2.2×19.9%

How Vigonvita Life Sciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Vigonvita Life Sciences against its 5 peers (data as of 18 Nov 2026)
Measure2630.HKPeer medianRank in peer set
1-month return-5.0%-10.5%3rd highest of 6
6-month return-4.9%-12.5%3rd highest of 6
Distance from 52-week high-43.7%-43.5%3rd lowest of 6
Revenue growth (TTM)+763.1%-3.9%highest of 6
Operating margin-327.4%0.5%lowest of 6
EV / Sales116.9×19.2×most expensive of 6
ROIC minus cost of capital-58.7 pp-3.5 pp2nd lowest of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Vigonvita Life Sciences 2630.HKHong Kong$1.59B-5%+763%-327%116.9×n/an/a
Neuren Pharmaceuticals NEU.AXAustralia$1.87B+52%-68%20%36.0×n/an/a
Suzhou Ribo Life Science 6938.HKHong Kong$860M-32%+4%-187%30.3×n/an/a
Realcan Pharmaceutical 002589.SZChina$581M-13%-4%0%0.9×16.9%-23.1%
Hikma Pharmaceuticals HIK.LUnited Kingdom$4.58B+15%+2%20%1.9×2.0%+6.8%
Tibet Duo Rui Pharmaceutical 301075.SZChina$487M-51%-6%-34%19.2×n/an/a

Questions

Who are Vigonvita Life Sciences's main competitors?
Named competitors: Junshi Biosciences (1877.HK), Simcere Pharmaceutical (2096.HK), Fosun Pharma (2196.HK). The cockpit's measured peer set (industry) also includes Neuren Pharmaceuticals (NEU.AX), Suzhou Ribo Life Science (6938.HK), Realcan Pharmaceutical (002589.SZ), Hikma Pharmaceuticals (HIK.L), Tibet Duo Rui Pharmaceutical (301075.SZ).
Is Vigonvita Life Sciences expensive compared with its peers?
On ev / sales it trades at 116.9× against a peer median of 19.2×, most expensive of 6 in its peer set.
How has Vigonvita Life Sciences stock performed?
Over six months to 18 Nov 2026 the shares returned -4.9% against -12.5% for the median peer; over one year +43.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.